Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vericel CorpVCEL · Entity 4481 | Director | April 29, 2026 | May 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vericel Corp
Report date April 29, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,995 |
Reported balance
After 2026-04-29 transaction · row 1
1 source rowRow 1 · 2026-04-29 · Exercise / conversion · Acquired 3,200 · Balance 32,995 F1: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 30, 2025. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-29 · Exercise / conversion · Acquired 3,200 · Balance 0 F2: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F3: These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025. F4: No expiration date for this type of award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 3,200 |
Reported balance
After 2026-04-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-29 · Grant · Acquired 3,200 · Balance 3,200 F2: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6: These RSUs vest 100% on the earlier of April 29, 2027, or the date of the first Annual Meeting of Stockholders following April 29, 2026. F4: No expiration date for this type of award. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.43 · Expires 2036-04-29 | Direct | 8,000 |
Reported balance
After 2026-04-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-29 · Grant · Acquired 8,000 · Balance 8,000 F5: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 30, 2025.
F2: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
F3: These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025.
F4: No expiration date for this type of award.
F5: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company.
F6: These RSUs vest 100% on the earlier of April 29, 2027, or the date of the first Annual Meeting of Stockholders following April 29, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 29, 2026 Filed May 1, 2026 20:06 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-018541 · form4.xml · derivative · entry 4 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,200 Underlying: Common Stock · 3,200 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 29, 2027, or the date of the first Annual Meeting of Stockholders following April 29, 2026. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 29, 2026 Filed May 1, 2026 20:06 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $33.43 | $0.00 |
DisclosureSEC source: 0001140361-26-018541 · form4.xml · derivative · entry 3 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2036-04-29 F5 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| April 29, 2026 Filed May 1, 2026 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-018541 · form4.xml · derivative · entry 2 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 29, 2026 Filed May 1, 2026 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 3,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-018541 · form4.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 30, 2025. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:07 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-017114 · form4.xml · derivative · entry 4 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,200 Underlying: Common Stock · 3,200 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:07 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $38.02 | $0.00 |
DisclosureSEC source: 0001140361-25-017114 · form4.xml · derivative · entry 3 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2035-04-30 F5 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:07 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-017114 · form4.xml · derivative · entry 2 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of May 1, 2025, or the date of the first Annual Meeting of Stockholders following May 1, 2024. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:07 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 3,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-25-017114 · form4.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on May 1, 2024. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:18 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001140361-25-003571 · form4.xml · derivative · entry 3 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 2,500 shares Expires 2028-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase 17,500 shares, were originally granted on May 2, 2018, becoming exercisable in equal monthly installments, contingent upon continued service to the Company, from June 2, 2018 through May 2, 2019. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:18 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 2,500 | $62.50 | $156,250.00 |
DisclosureSEC source: 0001140361-25-003571 · form4.xml · nonDerivative · entry 2 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,595 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2024. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:18 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 2,500 | $13.05 | $32,625.00 |
DisclosureSEC source: 0001140361-25-003571 · form4.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2024 Filed Nov 25, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001140361-24-047758 · form4.xml · derivative · entry 3 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 2,500 shares Expires 2028-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase 17,500 shares, were originally granted on May 2, 2018, becoming exercisable in equal monthly installments, contingent upon continued service to the Company, from June 2, 2018 through May 2, 2019. Read SEC document |
| November 22, 2024 Filed Nov 25, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 2,500 | $60.00 | $150,000.00 |
DisclosureSEC source: 0001140361-24-047758 · form4.xml · nonDerivative · entry 2 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,595 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2024. Read SEC document |
| November 22, 2024 Filed Nov 25, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 2,500 | $13.05 | $32,625.00 |
DisclosureSEC source: 0001140361-24-047758 · form4.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2024 Filed Nov 13, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001140361-24-046456 · form4.xml · derivative · entry 6 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 2,500 shares Expires 2028-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase 17,500 shares, were originally granted on May 2, 2018, becoming exercisable in equal monthly installments, contingent upon continued service to the Company, from June 2, 2018 through May 2, 2019. Read SEC document |
| November 12, 2024 Filed Nov 13, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 2,500 | $57.50 | $143,750.00 |
DisclosureSEC source: 0001140361-24-046456 · form4.xml · nonDerivative · entry 4 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,595 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2024. Read SEC document |
| November 12, 2024 Filed Nov 13, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 2,500 | $13.05 | $32,625.00 |
DisclosureSEC source: 0001140361-24-046456 · form4.xml · nonDerivative · entry 3 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001140361-24-046456 · form4.xml · derivative · entry 5 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 2,500 shares Expires 2028-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase 17,500 shares, were originally granted on May 2, 2018, becoming exercisable in equal monthly installments, contingent upon continued service to the Company, from June 2, 2018 through May 2, 2019. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 2,500 | $55.00 | $137,500.00 |
DisclosureSEC source: 0001140361-24-046456 · form4.xml · nonDerivative · entry 2 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,595 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2024. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 2,500 | $13.05 | $32,625.00 |
DisclosureSEC source: 0001140361-24-046456 · form4.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:06 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-024334 · form4.xml · derivative · entry 4 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,200 Underlying: Common Stock · 3,200 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · derivative.exercise_date: These RSUs vest 100% on the earlier of May 1, 2025, or the date of the first Annual Meeting of Stockholders following May 1, 2024. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:06 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $47.08 | $0.00 |
DisclosureSEC source: 0001140361-24-024334 · form4.xml · derivative · entry 3 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2034-05-01 F5 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-024334 · form4.xml · derivative · entry 2 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of May 3, 2024, or the date of the first Annual Meeting of Stockholders following May 3, 2023. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 3,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-024334 · form4.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on May 3, 2023. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,278 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001140361-24-016591 · form4.xml · derivative · entry 3 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,278 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase 4,000 shares, became exercisable in three installments, contingent upon continued service to the Company, with the first vesting date on March 20, 2015, which was the date on which the option was granted, and the final vesting date on May 1, 2015. F3 · derivative.expiration_date: These options, which were awarded on March 20, 2015, would otherwise expire and become forfeitable on March 20, 2025. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 20:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 3,278 | $51.57 | $169,046.46 |
DisclosureSEC source: 0001140361-24-016591 · form4.xml · nonDerivative · entry 2 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,395 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2023. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 3,278 | $3.74 | $12,259.72 |
DisclosureSEC source: 0001140361-24-016591 · form4.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:07 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 722 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001140361-24-009033 · form4.xml · derivative · entry 3 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,278 Underlying: Common Stock · 722 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase 4,000 shares, became exercisable in three installments, contingent upon continued service to the Company, with the first vesting date on March 20, 2015, which was the date on which the option was granted, and the final vesting date on May 1, 2015. F3 · derivative.expiration_date: These options, which were awarded on March 20, 2015, would otherwise expire and become forfeitable on March 20, 2025. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:07 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 722 | $50.01 | $36,107.22 |
DisclosureSEC source: 0001140361-24-009033 · form4.xml · nonDerivative · entry 2 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,395 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2023. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:07 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 722 | $3.74 | $2,700.28 |
DisclosureSEC source: 0001140361-24-009033 · form4.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2024 Filed Jan 30, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 2,300 | $44.22 | $101,706.00 |
DisclosureSEC source: 0001140361-24-004549 · form4.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,395 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2023. Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 200 | $44.02 | $8,804.00 |
DisclosureSEC source: 0001140361-24-004270 · form4.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,695 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2023. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001140361-24-003663 · form4.xml · derivative · entry 5 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase 3,000 shares, became exercisable in equal monthly installments, contingent upon continued service to the Company, with the first vesting date on June 7, 2014, which was one month after the date on which the option was granted. F3 · derivative.expiration_date: These options, which were awarded on May 7, 2014, would otherwise expire and become forfeitable on May 7, 2024. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 3,000 | $42.05 | $126,150.00 |
DisclosureSEC source: 0001140361-24-003663 · form4.xml · nonDerivative · entry 4 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,895 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2023. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 3,000 | $4.12 | $12,360.00 |
DisclosureSEC source: 0001140361-24-003663 · form4.xml · nonDerivative · entry 3 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 2,500 | $42.06 | $105,150.00 |
DisclosureSEC source: 0001140361-24-003663 · form4.xml · nonDerivative · entry 2 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,895 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2023. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 2,500 | $41.39 | $103,475.00 |
DisclosureSEC source: 0001140361-24-003663 · form4.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,395 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2023. Read SEC document |
| January 12, 2024 Filed Jan 16, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 2,200 | $38.09 | $83,798.00 |
DisclosureSEC source: 0001140361-24-002336 · form4.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,895 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2023. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 21:06 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 100 | $38.06 | $3,806.00 |
DisclosureSEC source: 0001140361-23-053861 · form4.xml · nonDerivative · entry 2 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,095 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2023. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 21:06 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 200 | $38.00 | $7,600.00 |
DisclosureSEC source: 0001140361-23-053861 · form4.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,195 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2023. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 20:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 1,000 | $38.84 | $38,840.00 |
DisclosureSEC source: 0001140361-23-034793 · form4.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,395 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2022. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 20:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 3,000 | $36.00 | $108,000.00 |
DisclosureSEC source: 0001140361-23-031408 · form4.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,395 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2022. Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:05 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-023197 · form4.xml · derivative · entry 2 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,200 Underlying: Common Stock · 3,200 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of May 3, 2024 or the date of the first Annual Meeting of Stockholders following May 3, 2023. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:05 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $32.12 | $0.00 |
DisclosureSEC source: 0001140361-23-023197 · form4.xml · derivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2033-05-03 F1 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 20:04 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-021501 · form4.xml · derivative · entry 2 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 27, 2023 or the date of the first Annual Meeting of Stockholders following April 27, 2022. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 20:04 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 2,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-021501 · form4.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 27, 2022. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:32 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-23-008724 · form4.xml · derivative · entry 2 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2023-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options, representing the right to purchase a total of 3,000 shares, were originally granted on May 2, 2013, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:32 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 3,000 | $10.60 | $31,800.00 |
DisclosureSEC source: 0001127602-23-008724 · form4.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 20:18 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $31.99 | $0.00 |
DisclosureSEC source: 0001593968-22-000893 · primary_01.xml · derivative · entry 4 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2032-04-27 F7 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 20:18 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000893 · primary_01.xml · derivative · entry 3 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600 Underlying: Common Stock · 2,600 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 27, 2023 or the date of the first Annual Meeting of Stockholders following April 27, 2022. Vested shares will be delivered to the Reporting Person following termination of service on the Company's Board of Directors. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.